en بیوشیمی Biochemistry مقالات اصلی Original Article <div style="text-align: justify;"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span style="tab-stops:396.55pt"><b><i><span lang="EN-CA" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Background:</span></span></i></b> <span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Immunological alterations in schizophrenic patients have been considered during last decade. There are no remarkable reports on the changes of IL-17A and IL-21 in schizophrenic patients. Therefore, the purpose of this study was to evaluate changes of serum IL-17A and IL-21 in schizophrenic patients in comparison with healthy controls.</span></span></span></span></span></span><br> <br> <span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span style="tab-stops:396.55pt"><b><i><span lang="EN-CA" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Methods:</span></span></i></b> <span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">In the present study serum levels of IL-17A and IL-21 in 30 patients with schizophrenia before treatment and three months after treatment were measured by enzyme-linked immunosorbent assay (ELISA) and compare to 30 match healthy control group.</span></span></span></span></span></span><br> <br> <span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span style="tab-stops:396.55pt"><b><i><span lang="EN-CA" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Results:</span></span></i></b> <span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Serum levels of IL-21 in schizophrenic patient was significantly higher than control group (P= 0.001). Serum levels of IL-17A in the schizophrenic patients had no significant changes than the control group (P= 0.4). Serum levels of IL-17A in patients with schizophrenia three months after treatment than before treatment had no significant change (P=0.7) and IL-21 serum levels in schizophrenic patient three month after treatment was not significant changed in comparison with this group before treatment (P= 0.06).</span></span><br> <b><span dir="RTL" lang="FA" style="font-size:12.0pt"><span style="font-family:"Times New Roman",serif"></span></span></b></span></span></span></span><br> <span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:normal"><span style="tab-stops:396.55pt"><b><i><span lang="EN-CA" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">Conclusions:</span></span></i></b> <span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times="">The serum levels of interlukine-21 is elevated in schizophrenic. Results of this study showed that IL-21 might be involved in the pathologic mechanism of schizophrenia.</span></span></span></span></span></span></div> Keywords: Immunity, Interleukin-17A, Interleukin-21, Schizophrenia. 465 470 http://rbmb.net/browse.php?a_code=A-10-1009-1&slc_lang=en&sid=1 Seyed Ali Miresmaeili Mazrakhondi Seyyed.ali.miresmaeily136568@gmail.com. 100319475328460016734 100319475328460016734 Yes Department of Biology, Faculty of Basic Science, Yazd University, Yazd, Iran. Hadi Zare-Zardini 100319475328460016735 100319475328460016735 No Department of Biomedical Engineering, Meybod University, Meybod, Iran & Hematology and Oncology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran & Medical Nanotechnology & Tissue Engineering Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.